Adagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFeb 2, 2026 8:05 AM Eastern Standard Time# Adagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceShare---LAGUNA HILLS, Calif.--([BUSINESS WIRE])--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio†or "the Company†), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today a ...

LAGUNA HILLS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Adagio Medical Holdings, Inc. (NASDAQ: ADGM), based in Laguna Hills, CA, a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Company management will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on February 5, 2026 DATE: February 5thTIME: 1:30 PM ET REGISTER HERE Available for 1x1 meetings: February 12 and 13. Schedule 1x1 Meeti ...

Company secures first purchase order and multi-year commitment at Ireland’s largest electrophysiology centerFort Mill, SC, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a leader in advanced electrophysiology solutions, today announced the successful implementation of LockeT and the first LockeT purchase order at Mater Private Hospital, located in Dublin, Ireland. This marks a significant milestone in the company’s global expansion strategy and reinforces its commitment ...

Core Insights - Adagio Medical Holdings, Inc. announced preliminary results from the FULCRUM-VT Study, demonstrating 97.4% acute clinical success in treating Sustained Monomorphic Ventricular Tachycardia (SMVT) using their proprietary Ultra-Low Temperature Cryoablation (ULTC) technology [1][2][5] Study Overview - The FULCRUM-VT Study involved 207 patients across 19 sites in the U.S. and Canada, focusing on both ischemic and non-ischemic cardiomyopathy [2][8] - The study reported a mean procedure duration of 206 minutes and a 2.5% rate of major adverse events, including four peri-procedural deaths [2][4] Efficacy and Safety Results - Acute clinical success was defined as the non-inducibility of target ventricular arrhythmias, achieved in 97.4% of cases, with 96.7% of patients having all clinically relevant ventricular tachycardias eliminated [2][4] - The safety profile of the ULTC system was deemed favorable, with a low rate of major adverse events [4][5] Future Outlook - The company plans to present six-month primary efficacy endpoint results at the Heart Rhythm 2026 conference, indicating ongoing commitment to research and development [4][5] - The FULCRUM-VT Study aims to support FDA premarket approval for the vCLAS™ Cryoablation System, potentially leading to broader indications for treating scar-mediated VT [8][9]

Core Insights - Catheter Precision, Inc. has successfully completed the first LockeT procedures in France, marking a significant step in the adoption of its cardiac electrophysiology technologies in Europe [1][2] - The procedures were conducted at CHU Rennes, which is also a commercial partner for the company's VIVO product line [2] - The LockeT device is designed to improve procedural efficiency and patient outcomes following cardiac ablation procedures, indicating a strong market need in Europe [3] Product Information - LockeT is a suture retention device aimed at assisting in wound closure after percutaneous venous punctures, classified as a Class 1 device with FDA registration and CE Mark approval [4] - VIVO (View Into Ventricular Onset) is a non-invasive 3D imaging system that helps identify the origin of ventricular arrhythmias before procedures, thus streamlining workflow and reducing procedure time; it has also received FDA marketing clearance and CE Mark [5] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the treatment of cardiac arrhythmias, emphasizing collaboration with physicians and continuous product advancement [6]

Group 1 - Catheter Precision, Inc. has received its largest purchase order to date from Centre Hospitalier Universitaire (CHU) de Rennes for its VIVO product line [1] - CHU Rennes serves nearly 500,000 patients annually and is recognized for its mission in teaching, research, and innovation [2] - The hospital performs over 150 ventricular ablations (VA) per year, positioning it as one of the largest centers for this procedure in Europe [3] Group 2 - The VIVO system is a non-invasive 3D imaging technology that helps physicians identify the origin of ventricular arrhythmias before procedures, enhancing workflow and reducing procedure time [4] - Catheter Precision focuses on developing innovative solutions for cardiac arrhythmias and collaborates with physicians to advance its product offerings [5]